Bipolar II Depression: Lithium, SSRI, or the Combination

PHASE3CompletedINTERVENTIONAL
Enrollment

139

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

March 31, 2012

Study Completion Date

July 31, 2012

Conditions
Bipolar DisorderDepression
Interventions
DRUG

Sertraline

Sertraline or placebo for sertraline starting at 25 mg per day, up to maximum of 200 mg per day

DRUG

Lithium carbonate

Lithium or placebo for lithium starting at 150 mg per day; target dose of 900mg per day. Maximum dose based on clinical response and serum levels (maximum serum level of 1.2 mEq/L).

Trial Locations (3)

45040

Lindner Center of HOPE, affliated with University of Cincinnati Medical Center, Mason

90095

UCLA, Los Angeles

94304

Stanford University - Bipolar Research Program, Palo Alto

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

collaborator

University of California, Los Angeles

OTHER

collaborator

Stanford University

OTHER

lead

Lindner Center of HOPE

OTHER

NCT00276965 - Bipolar II Depression: Lithium, SSRI, or the Combination | Biotech Hunter | Biotech Hunter